Loading...

Orchard Therapeutics

DB:OT1A
Snowflake Description

Moderate growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OT1A
DB
$1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The last earnings update was 136 days ago. More info.


Add to Portfolio Compare Print
  • Orchard Therapeutics has significant price volatility in the past 3 months.
OT1A Share Price and Events
7 Day Returns
0%
DB:OT1A
3.2%
DE Biotechs
3%
DE Market
1 Year Returns
-
DB:OT1A
-3.6%
DE Biotechs
-12%
DE Market
OT1A Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Orchard Therapeutics (OT1A) 0% 0% 0% - - -
DE Biotechs 3.2% -4% -1% -3.6% 88.3% 10.4%
DE Market 3% 2.9% -0.7% -12% 11.9% 5.1%
1 Year Return vs Industry and Market
  • No trading data on OT1A.
  • No trading data on OT1A.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Orchard Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Orchard Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Orchard Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Orchard Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €17.154.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Orchard Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Orchard Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:OT1A PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in USD $-13.68
NasdaqGS:ORTX Share Price ** NasdaqGS (2018-11-19) in USD $15.25
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 27.93x
Germany Market PE Ratio Median Figure of 420 Publicly-Listed Companies 18.08x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Orchard Therapeutics.

DB:OT1A PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ORTX Share Price ÷ EPS (both in USD)

= 15.25 ÷ -13.68

-1.11x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Orchard Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Orchard Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Orchard Therapeutics's expected growth come at a high price?
Raw Data
DB:OT1A PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.11x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
33.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 21 Publicly-Listed Biotechs Companies 1.45x
Germany Market PEG Ratio Median Figure of 276 Publicly-Listed Companies 1.45x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Orchard Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Orchard Therapeutics's assets?
Raw Data
DB:OT1A PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in USD $-15.63
NasdaqGS:ORTX Share Price * NasdaqGS (2018-11-19) in USD $15.25
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 2.39x
Germany Market PB Ratio Median Figure of 566 Publicly-Listed Companies 1.79x
DB:OT1A PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ORTX Share Price ÷ Book Value per Share (both in USD)

= 15.25 ÷ -15.63

-0.98x

* Primary Listing of Orchard Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Orchard Therapeutics has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at Orchard Therapeutics's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Orchard Therapeutics's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Orchard Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Orchard Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Orchard Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
33.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Orchard Therapeutics expected to grow at an attractive rate?
  • Orchard Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Orchard Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Orchard Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:OT1A Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:OT1A Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 33.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 29.7%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 28.5%
Germany Market Earnings Growth Rate Market Cap Weighted Average 9.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:OT1A Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (7 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:OT1A Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 382 46 2
2022-12-31 191 -27 2
2021-12-31 52 -115 2
2020-12-31 3 -279 -256 4
2019-12-31 2 -265 -252 4
2018-12-31 5 -198 -251 4
DB:OT1A Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-06-30 -59 -165
2018-03-31 -46 -102
2017-12-31 -32 -40
2016-12-31 -15 -19

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Orchard Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Orchard Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:OT1A Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (7 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Orchard Therapeutics Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:OT1A Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.37 0.72 0.01 2.00
2022-12-31 -0.29 0.18 -0.75 2.00
2021-12-31 -1.15 -0.59 -1.70 2.00
2020-12-31 -2.46 -1.95 -3.20 3.00
2019-12-31 -2.70 -2.21 -3.50 3.00
2018-12-31 -3.69 -2.23 -6.37 3.00
DB:OT1A Past Financials Data
Date (Data in USD Millions) EPS *
2018-06-30 -13.68
2018-03-31 -8.85
2017-12-31 -3.58
2016-12-31 -2.15

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Orchard Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Orchard Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Orchard Therapeutics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Orchard Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Orchard Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Orchard Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Orchard Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Orchard Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Orchard Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Orchard Therapeutics Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:OT1A Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 -165.17 15.66 149.20
2018-03-31 -102.46 10.82 90.86
2017-12-31 -39.74 5.99 32.53
2016-12-31 -19.09 3.00 16.21

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Orchard Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Orchard Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Orchard Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Orchard Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Orchard Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Orchard Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Orchard Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Orchard Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Orchard Therapeutics's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Orchard Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Orchard Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Orchard Therapeutics Company Filings, last reported 7 months ago.

DB:OT1A Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 45.42 0.00 48.76
2018-03-31 45.42 0.00 48.76
2017-12-31 86.41 0.00 89.86
2016-12-31 0.45 0.00 3.50
  • Orchard Therapeutics has no debt.
  • Orchard Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Orchard Therapeutics has less than a year of cash runway based on current free cash flow.
  • Orchard Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 74.8% each year.
X
Financial health checks
We assess Orchard Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Orchard Therapeutics has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Orchard Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Orchard Therapeutics dividends.
If you bought €2,000 of Orchard Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Orchard Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Orchard Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:OT1A Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
Germany Market Average Dividend Yield Market Cap Weighted Average of 330 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:OT1A Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Orchard Therapeutics has not reported any payouts.
  • Unable to verify if Orchard Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Orchard Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Orchard Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Orchard Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Orchard Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Orchard Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Orchard Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mark Rothera
AGE 55
CEO Bio

Mr. Mark A. Rothera has been Chief Executive Officer, President, and Director of Orchard Therapeutics Limited since August 14, 2017. Mr. Rothera serves as Consultant of PTC Therapeutics, Inc. since August 9, 2017. Mr. Rothera served as Chief Commercial Officer of PTC Therapeutics, Inc. since April 2013 until August 9, 2017. He served as the Global President of Aegerion Pharmaceuticals Inc. since December 7, 2011. He served as Vice President and General Manager of commercial operations for Europe, Middle East & Africa at Shire Human Genetic Therapies, the division of Shire. In this role, he built commercial infrastructure to had Shire's orphan drugs to patients in 40 countries and lead the EMEA management team comprising all key regional functions and country/regional operational managers. During his six years with Shire HGT, he successfully launched three new orphan drug products and significantly grew the organization's global revenues. Prior to Shire Human Genetic Therapies, Mr. Rothera held key commercial positions with early stage, growth companies including ADL Healthcare Ltd., Chiron Biopharmaceuticals Europe Ltd., PathoGenesis Europe and Amylin Pharmaceuticals Europe. In 1998, he began his involvement with rare diseases by launching a product for Cystic Fibrosis. Mr. Rothera received an M.A. in Natural Science from Cambridge University, an M.B.A. from the European Institute for Business Administration and a Diploma in Company Direction from Institute of Directors, UK.

CEO Compensation
  • Insufficient data for Mark to compare compensation growth.
  • Insufficient data for Mark to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Mark Rothera

TITLE
CEO, President & Director
AGE
55

Anne Dupraz-Poiseau

TITLE
Chief Regulatory Officer

Frank Thomas

TITLE
CFO & Chief Business Officer
AGE
48

Bobby Gaspar

TITLE
Chief Scientific Officer
AGE
54

John Ilett

TITLE
General Counsel & Company Secretary

Nicolas Koebel

TITLE
Chief of Staff & Head of Program Management and Corporate Communications

John Cerio

TITLE
Global Head of Human Resources & Senior VP

Andrea Spezzi

TITLE
Chief Medical Officer

Stewart Craig

TITLE
Chief Manufacturing Officer
AGE
56

Jason Meyenburg

TITLE
Chief Commercial Officer
Board of Directors

Jim Geraghty

TITLE
Chairman of the Board
AGE
63

Mark Rothera

TITLE
CEO, President & Director
AGE
55

Bobby Gaspar

TITLE
Chief Scientific Officer
AGE
54

Charlie Rowland

TITLE
Director
AGE
60

Alessandra Biffi

TITLE
Member of Scientific Advisory Board

Brian Bigger

TITLE
Member of Scientific Advisory Board

Simon Jones

TITLE
Member of Scientific Advisory Board

Don Kohn

TITLE
Member of Scientific Advisory Board

Adrian Thrasher

TITLE
Member of Scientific Advisory Board

David Williams

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Orchard Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Orchard Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Map
Description

Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company’s gene therapy approach seeks to transform a patient’s hematopoietic stem cells into a gene-modified drug product to treat the patient’s disease through a single administration. Its commercial stage products include Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company’s clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-201 for mucopolysaccharidosis type IIIA and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Ltd. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Details
Name: Orchard Therapeutics plc
OT1A
Exchange: DB
Founded: 2015
$1,161,475,160
85,865,057
Website: http://www.orchard-tx.com
Address: Orchard Therapeutics plc
108 Cannon Street,
London,
Greater London, EC4N 6EU,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ORTX ADS Nasdaq Global Select US USD 31. Oct 2018
DB OT1A ADS Deutsche Boerse AG DE EUR 31. Oct 2018
Number of employees
Current staff
Staff numbers
100
Orchard Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/02/17 00:13
End of day share price update: 2018/11/19 00:00
Last estimates confirmation: 2018/12/17
Last earnings filing: 2018/10/04
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.